Evidence-Based Pharmacological Treatment of Substance Use Disorders and Pathological Gambling

Brink, W. van den

doi:10.2174/1874473711205010003

Cited by 99 publications

(49 citation statements)

References 265 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This sample size was indicated by the dichotomous primary outcome variable (transition or no transition). This requires maximum likelihood models with sample sizes of at least 100 participants plus 10 extra participants for each parameter that needs to be estimated [55]. Thus for a multiple regression model with a liberal amount of nine predictors 200 participants are needed per cohort, with an additional 20% to allow for attrition.…”

Section: Target Populationmentioning

confidence: 99%

The dynamics of cannabis use and dependence

Pol¹

2016

European Neuropsychopharmacology

View full text Add to dashboard Cite

Section: Target Populationmentioning

confidence: 99%

The dynamics of cannabis use and dependence

Pol¹

2016

European Neuropsychopharmacology

View full text Add to dashboard Cite

“…The natural course of AUD varies vastly; from very positive outcomes reported in general population samples meeting alcohol abuse or dependence criteria to very negative outcomes in treatment seeking patients in criminal justice settings [12] . Overall, most affected individuals recover naturally without any formal type of treatment, and approximately 70% of individuals go into remission within three years [13,14] .…”

Section: Two Types Of Aud Patientsmentioning

confidence: 99%

“…A small number of medications are registered for the treatment of AUDs (disulfiram, naltrexone, acamprosate, nalmefene) while some other medications have shown promise mainly in short-term studies (e.g., topiramate, GHB, baclofen, and gabapentin) [12] . While most of these treatments take abstinence as main treatment goal, recently interest is growing for a reduction of alcohol use as a valid treatment goal [39,40] .…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

See 1 more Smart Citation

Addiction specialist's role in liver transplantation procedures for alcoholic liver disease

Dom¹

2015

WJH

View full text Add to dashboard Cite

Although liver transplantation (LT) is performed increasingly for patients with end-stage alcoholic liver disease (ALD), the topic remains controversial. Traditionally, the role of an addiction specialist focused on the screening and identification of patients with a high risk on relapse in heavy alcohol use. These patients were in many cases subsequently excluded from a further LT procedure. Recently, awareness is growing that not only screening of patients but also offering treatment, helping patients regain and maintain abstinence is essential, opening up a broader role for the addiction specialist (team) within the whole of the transplant procedure. Within this context, high-risk assessment is proposed to be an indication of increasing addiction treatment intensity, instead of being an exclusion criterion. In this review we present an overview regarding the state of the art on alcohol relapse assessment and treatment in patients with alcohol use disorders, both with and without ALD. Screening, treatment and monitoring is suggested as central roles for the addiction specialist (team) integrated within transplant centers.

show abstract

“…To date, there are no significant interventional studies or animal models. In fact, all web analyses are purely observational, though attempts for quasi-experimental studies are emerging (Hegde et al, 2013;Van den Brink, 2012). These methods are not only highly time-consuming and requires advanced resources, including, financial, human, chemical analysis, and legislative resources, but they are also mere observations which are obsolete beyond the point of time in which they were taken (Nizar et al, 2015;Vermette-Marcotte et al, 2014;Wood & Dargan, 2014).…”

Section: Introductionmentioning

confidence: 99%